- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Mariam Lewis on Why Women Are More Vulnerable to Effects From Tobacco
Mariam Lewis, MD, FCCP, a pulmonologist at UF Health and the UF College of Medicine, discusses why women are more sensitive to the effects of tobacco.
Mariam Lewis, MD, FCCP, a pulmonologist at UF Health, and co-medical director, Sleep Lab, in Jacksonville, Florida; and associate professor, Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, at the UF College of Medicine, discusses why women are more sensitive to the effects of tobacco.
Transcript
Why are women more sensitive to the effects of tobacco smoke?
So that's a really good question. It's probably multiple reasons. Genetics plays a factor—so just if you're more susceptible to it genetically. Hormones—we know that women are much more susceptible because of the effects of estrogen. Probably the X chromosome in and of itself. And then the development of the lung is different between girls and boys. And so all of those combined together make it more likely that women are more susceptible to the effects of tobacco compared to men.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
